Trials / Completed
CompletedNCT04594850
Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously
An Single-blind, Multi-center, Randomization, Phase Ⅱ Study to Evaluate Efficacy and Safety of Cellgram-ED (Autologous Bone Marrow-derived Mesenchymal Stem Cells) in Erectile Dysfunction Patients With Following Radical Prostatectomy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Pharmicell Co., Ltd. · Industry
- Sex
- Male
- Age
- 19 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
This phase II clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.
Detailed description
To evaluate the efficacy and efficacy for 12 months after a single dose of Cellgram-ED in patients with erectile dysfunction after radical prostatectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cellgram-ED | Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously. |
Timeline
- Start date
- 2020-10-19
- Primary completion
- 2026-01-07
- Completion
- 2026-01-07
- First posted
- 2020-10-20
- Last updated
- 2026-02-09
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04594850. Inclusion in this directory is not an endorsement.